Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMSCs for Recurrent Glioblastoma
NCT05789394Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2023
- Primary completion
- Jul 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CSCC_ASC in glioblastoma (GBM) and astrocytoma, sponsored by Mayo Clinic. Primary endpoint: Maximum tolerated dose at 4 weeks. Started Jun 2023; status: recruiting.
02
Drugs
CSCC_ASC
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT05789394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789394.